Shots:

• Liquidia Corporation’s Yutrepia (Treprostinil) inhalation powder has received the US FDA’s tentative approval to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
• The tentative approval was based on the P-III (INSPIRE) study assessed adults who had not previously been treated with treprostinil, along with those switching from nebulized treprostinil to Yutrepia. These data were published in the Pulmonary Circulation Journal in 2022 and the Vascular Pharmacology Journal in 2021
• The final approval of YUTREPIA for PAH & PH-ILD could take place following the end of the three-year regulatory exclusivity for Tyvaso DPI, which expires on May 23, 2025

Ref: Liquidia | Image: Liquidia

Related News:- Liquidia and Pharmosa Biopharm Enters into Exclusive Licensing Agreement for $225M to Develop and Commercialize L606 in North America

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com